Bispecific antibodies (BsAbs) continue to garner the interest of both academic and community cancer centers due to their rapid growth in FDA approvals and increasing use in hematologic malignancies and solid tumors. However, practical considerations such as treatment-related toxicities, choosing the right delivery model, and staffing constraints deter many programs from attempting to implement BsAbs.

In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP, an Outpatient Hematology Advanced Practice Provider (APP) Team Lead at Vanderbilt-Ingram Cancer Center, about her program's APP-led BsAb step-up dosing clinic. With APPs at the helm, this model enables efficient and specialty-expert management of therapies while optimizing physician resources. In addition, its adherence to step-up dosing protocols prioritizes patient safety and convenience while reducing inpatient resource utilization.

"[It's important to look] at what you need to spend money on, [make] sure that you're spending money on the right things, and then [look] for areas like space and staff that maybe have capacity that you can utilize in a little bit of a different way to deliver this care." – Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP

Guest:
Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP
Outpatient Hematology APP Team Lead
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Resources:

• ACCC 43rd National Oncology Conference

• 2026 ACCC Innovator Vanderbilt-Ingram Cancer Center

• Blog: An APP-Led Outpatient Bispecific Antibody Clinic

• Podcast: APPs Paving the Way in Leadership

• Blog: Maximizing the Role of APPs in Oncology Care

• Blog: Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions